Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor

Ken Ichi Hiasa, Kensuke Egashira, Shiro Kitamoto, Minako Ishibashi, Shujiro Inoue, Weihua Ni, Qingwei Zhao, Shin Nagata, Makoto Katoh, Masataka Sata, Akira Takeshita

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

No prior study has examined the effect of intravenous injection of bone marrow mononuclear cells (MNCs) on myocardial infarction size (IS). We tested the hypothesis that transplantation of MNCs decreases IS through the release of vascular endothelial growth factor (VEGF). Immediately after ligation of the left coronary artery of immunodeficient mice, PBS or MNCs were intravenously administered. Myocardial IS was significantly less in MNCs-treated mice than in PBS-treated mice. Trace experiments showed accumulation of exogenously administered MNCs into the vicinity of infarcted myocardium. Injection of MNCs did not affect capillary density after infarction, but did reduced myocardial cell apoptosis. Blockade of VEGF by a neutralizing antibody or by gene transfer of a soluble form of Flt-1 VEGF receptor diminished the IS-limiting effects of MNCs. In conclusion, injection of MNCs can reduce myocardial IS through the release of VEGF. The MNC therapy for acute myocardial infarction might improve prognosis of patients with myocardial infarction.

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalBasic Research in Cardiology
Volume99
Issue number3
DOIs
Publication statusPublished - May 1 2004

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this